20:35:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning BONEX 0.00 SEK
2024-05-16 Årsstämma 2024
2024-04-25 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning BONEX 0.00 SEK
2023-05-17 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning BONEX 0.00 SEK
2022-05-19 Årsstämma 2022
2022-05-04 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning BONEX 0.00 SEK
2021-05-20 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-17 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning BONEX 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-08 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-25 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning BONEX 0.00 SEK
2019-05-14 Årsstämma 2019
2019-05-02 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-23 Ordinarie utdelning BONEX 0.00 SEK
2018-05-22 Årsstämma 2018
2018-05-04 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-02 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bonesupport är verksamt inom medicinteknik. Bolaget utvecklar och kommersialiserar injicerbara biokeramiska bengraftsubstitut som ombildas till patientens eget ben och har förmåga att frisätta läkemedel. Bolagets bengraftsubstitut är baserade på teknologiplattformen Cerament. I dagsläget genomför bolaget löpande kliniska studier. Bolaget innehar försäljning i Europa och Nordamerika och huvudkontoret ligger i Lund.
2023-05-17 14:11:00

BONESUPPORT, a leading company in orthobiologics for the management of bone injuries, announces that the company’s annual shareholders’ meeting was held on this day and that all resolutions were adopted with the required majority of votes.

The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board, and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed.

Allocation of the company’s result

The annual general meeting resolved to allocate the company’s result in accordance with the Board’s proposal, entailing that no dividends are paid and that available total funds of SEK 1,205,708,721 are carried forward.

Election of and remuneration for Board and auditor

The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Håkan Björklund, Björn Odlander, Lennart Johansson, Mary I O’Connor and Christine Rankin as ordinary Board members. Lennart Johansson was re-elected as chairman of the Board.

The annual general meeting furthermore resolved in accordance with the proposal from the Nomination Committee that Board remuneration shall be paid with SEK 450,000 to the chairman of the Board and with SEK 225,000 to each of the other Board members who are not employed by the company. Remuneration for committee work shall be paid with SEK 150,000 to the chair of the Audit Committee, with SEK 75,000 to each of the other members of the Audit Committee, with SEK 60,000 to the chair of the Remuneration Committee and with SEK 30,000 to each of the other members of the Remuneration Committee. It was furthermore resolved that additional remuneration of SEK 100,000 (corresponding to approximately USD 10,000) shall be paid to the Board member Mary I O’Connor as compensation for lost time due to travel to and from the company.

The annual general meeting furthermore resolved in accordance with the proposal from the Nomination Committee that the Board members Lennart Johansson, Mary I O'Connor and Christine Rankin together shall receive an extended Board remuneration of a total of SEK 900,000, subject to (i) the Board member acquiring shares in BONESUPPORT HOLDING AB for the entire extended Board remuneration (after tax) as soon as possible after the annual general meeting's resolution and the payment of the extended Board remuneration, and (ii) the Board member undertakes not to sell the shares during the Board member's entire term of office at BONESUPPORT HOLDING AB. The extended Board remuneration shall be distributed as follows: SEK 450,000 to the chairman of the Board and SEK 225,000 to each of Mary I O'Connor and Christine Rankin. In the event that the Board member before the next annual general meeting is dismissed as a result of breach of his or her obligations as a Board member or leaves the Board at his or hers own request, the Board member is obliged to repay the entire extended Board remuneration (after tax).

The annual general meeting also resolved to re-elect Ernst & Young AB as audit firm and that remuneration for the auditor shall be paid in accordance with invoiced amounts according to customary charging standards. Ernst & Young AB has informed that Henrik Rosengren will continue to be appointed as the auditor in charge.

Instruction and charter for the Nomination Committee

The annual general meeting resolved in accordance with the proposal from the Nomination Committee to adopt a new instruction and charter for the Nomination Committee, entailing that the Nomination Committee shall consist of three members, appointed by the three largest shareholders as per the end of September. The chairman of the Board is responsible to convene the Nomination Committee to its first meeting, and shall also be co-opted to the Nomination Committee, except when the Nomination Committee shall address to the matter of chairman of the Board and remuneration to the chairman of the Board.

Guidelines for remuneration to senior executives

The annual general meeting resolved in accordance with the proposal from the Board to adopt revised guidelines for remuneration to senior executives. In relation to the previous guidelines, the resolution entails that the company’s CFO shall be able to receive a variable cash remuneration amounting to a maximum of 52.5 percent of the fixed annual salary, compared to previously 40 percent of the fixed annual salary.

Authorization for the Board to resolve on new issues

The annual general meeting resolved in accordance with the proposal from the Board to authorize the Board, at one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders’ preferential rights, and with or without provisions regarding payment in kind or through set-off or other provisions, to resolve to issue new shares, convertibles and/or warrants. The total number of shares that that may be issued (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall not exceed 13,011,115 shares, which corresponds to a dilution of approximately 20 percent calculated on the current number of ordinary shares in the company. The purpose of the authorization and reason for any deviation from the shareholders’ preferential rights is to enable the company to raise working capital, to execute acquisitions of companies or operating assets as well as to enable issues to industrial partners within the framework of partnerships and alliances. To the extent an issue is made with deviation from the shareholders’ preferential rights, the issue should be made on market terms.

Implementation of a long-term incentive program for senior executives and other key employees through (A) implementation of a performance-based share saving program; (B) authorization on directed issues of series C shares; (C) authorization on repurchase of series C shares; and (D) resolution on transfer of own ordinary shares

The annual general meeting resolved in accordance with the proposal from the Board to implement a long-term incentive program for employees, LTI 2023, which entails that the participants will invest in a predetermined number of shares in the company and, subject to fulfilment of certain conditions, that they will be entitled to receive a predetermined number of shares free of charge, so called performance shares, at the end of 2026. The total number of performance shares according to LTI 2023 shall not exceed 664,000.

The annual general meeting furthermore resolved in accordance with the proposal from the Board to approve hedging measures to secure delivery of performance shares to the participants in LTI 2023 and therewith associated costs. The hedging measures include (i) an authorization for the Board to issue up to 486,840 series C shares, (ii) an authorization for the Board to repurchase all the issued series C shares, and (iii) a resolution to transfer no more than 664,000 series C shares, after conversion to ordinary shares, to participants in LTI 2023. In addition to newly issued series C shares according to the issue authorization mentioned above, 330,000 existing series C shares issued in connection with previous incentive programs, but which are no longer required for the performance of the company’s commitments under such programs, are intended to be used to secure delivery of performance shares to participants in LTI 2023 and to secure therewith associated costs.

Authorization for the Board to transfer own shares

The annual general meeting resolved in accordance with the proposal by the Board to authorize the Board, at one or several occasions, during the time up until the next annual general meeting, to resolve on transfer of the company’s ordinary shares on Nasdaq Stockholm at a price within the price interval registered at that time, meaning the interval between the highest purchase price and the lowest selling price. A maximum number of 133,000 ordinary shares may be transferred. The purpose of the authorization is to allow the company to sell shares in its own holding for cash flow hedging of social security charges arising upon delivery of shares to participants in LTI 2021 and Board LTI 2021, according to the terms of the programs.

Lund on May 17, 2023